Clofarabine versus fludarabine-based reduced-intensity conditioning regimen prior to allogeneic transplantation in adults with AML/MDS

Affiliation auteurs!!!! Error affiliation !!!!
TitreClofarabine versus fludarabine-based reduced-intensity conditioning regimen prior to allogeneic transplantation in adults with AML/MDS
Type de publicationJournal Article
Year of Publication2016
AuteursChevallier P, Labopin M, De La Tour RPeffault, Lioure B, Bulabois C-E, Huynh A, Blaise D, Turlure P, Daguindau E, Maillard N, Yakoub-Agha I, Guillerm G, Delage J, Contentin N, Bay J-O, Beckerich F, Bourhis J-H, Detrait M, Vigouroux S, Francois S, Legrand F, Guillaume T, Mohty M, -TC SFGM
JournalCANCER MEDICINE
Volume5
Pagination3068-3076
Date PublishedNOV
Type of ArticleArticle
ISSN2045-7634
Mots-clésacute myeloid leukemia, Allogeneic stem cell transplantation, clofarabine, fludarabine, Myelodysplastic Syndrome, reduced-toxicity conditioning regimen
Résumé

{We have retrospectively compared survivals between acute myeloid leukemia (AML)/myelodysplastic syndrome (MDS) patients who received either a clofarabine/busulfan (CloB2A2) or a fludarabine/busulfan (FB2A2) RIC regimen for allogeneic stem cell transplantation. Between 2009 and 2014, 355 allotransplanted cases were identified from the SFGM-TC registry as having received either the FB2A2 (n = 316, 56% males, median age: 59.2 years, AML 78.5%, first complete remission [CR1] 72%, median follow-up: 20 months) or the CloB2A2 (n = 39, 62% males, median age: 60.8 years, AML 62%, CR1 69%, median follow-up: 22.4 months) RIC regimen. In multivariate analysis, FB2A2 was associated with significant lower overall survival (OS, HR: 2.14; 95% CI: 1.05-4.35
DOI10.1002/cam4.880